Organic Active Ingredients TRIZ Cases

By targeting MTA-bound PRMT5 in MTAP-null cancer cells, these compounds improve tumor selectivity while limiting myelosuppression and normal tissue effects.

2′-F, 2′-Me, phosphorothioate, and abasic modifications improve nucleic acid stability while preserving target gene inhibition.

Combining CLK/DYRK inhibitors with venetoclax sensitizes resistant leukemia cells, promotes apoptosis, and helps delay relapse.

Novel AMPA receptor PAM compounds tune receptor binding to enhance cognition and synaptic plasticity while lowering convulsant risk.

Controlled-release pαKG microparticles prevent rapid αKG metabolism and diffusion, enabling immune modulation and improved tissue regeneration.

P-gp substrate CB1 blockers with low brain exposure preserve metabolic efficacy in peripheral organs while avoiding CNS side effects.

Targeted pyrazolo[1,5-a]pyridine TRPM3 antagonists address pain and inflammatory hypersensitivity while improving side-effect and pharmacokinetic profiles.

A thin oral film replaces hard-to-swallow lurasidone tablets with rapid saliva dissolution, better taste, and improved compliance.

Rapid centanafadine dosing and flexible monotherapy or add-on use target slow antidepressant onset with effective symptom relief and low adverse events.

Novel Formula I compounds modulate YAP/TEAD binding to reduce target gene expression and produce anti-proliferative effects.

Modified bile acid derivatives activate FXR to address inadequate cognitive therapies and help protect against impairment and cellular senescence.

Species-specific recombinant MG-53 proteins improve membrane repair and wound healing across animals, reducing scarring and supporting tissue regeneration.

Novel compounds tune YAP/TEAD binding to lower target-gene expression and deliver anti-proliferative effects in Hippo pathway diseases.

Pre-dosing DMT with a long-acting tryptamine helps buffer rapid onset, reducing anxiety and disorientation while preserving positive effects.

Defined crystalline salt forms improve TYK2 selectivity over JAK2 and enable PXRD-based solid-state control for safer therapeutic use.

Targeting the HSV helicase-primase complex, cyclic urea thiazolyl compounds improve antiviral potency while reducing adverse effects.

A Monascinol-based composition reduces liver fat, AST and ALT while improving gut microbiota for safer NAFLD treatment.

Branched hydrophobic tails improve ionization at endosomal pH and membrane fusion, boosting lipid nanoparticle delivery of mRNA and siRNA.

A minoxidil powder blended with dry shampoo supports hair growth while absorbing scalp oil, avoiding residue buildup and daily washing.

Covalent CPP-melphalan conjugates enable eye-drop delivery to the posterior ocular segment, improving absorption without intraocular injection.

Gastro-resistant tablets release bile acid sequestrants in the ileum and colon to reduce diarrhea while limiting upper GI side effects.

Ion-exchange resin complexes slow oral drug release for 8-24 hours while reducing extraction in non-gastric media to deter tampering and abuse.

Salt and prodrug forms of indoximod improve solubility, absorption, and plasma exposure to overcome its non-linear oral pharmacokinetics.

A narrow DHEAS alkanoyl ester range treats atherosclerosis and valvular calcification while reducing oxidative stress, toxicity, and hormonal effects.

A triazole-glucosamine formulation inhibits mycobacterial growth, including resistant strains, while improving stability and bioavailability.

Interconnected channels in a 3D-printed solid dosage form improve fluid percolation for more predictable drug release and rapid disintegration.

Dual CYP17A1 and AKT inhibition addresses androgen-AR and PI3K/AKT escape pathways to improve prostate cancer treatment response.

A self-emulsifying capsule delivers poorly water-soluble actives in clear beverages, improving bioavailability without consumer mixing.

A Formula IV compound protects vascular endothelium during thrombolytic or anticoagulant therapy, reducing hemorrhage and blood-brain barrier damage.

A Monascus pilosus fermented composition supports weight loss by shifting gut microbiota toward beneficial bacteria and lowering the Firmicutes ratio.

Genetic screening of mGluR network alterations guides fasoracetam use to reduce tics and improve ADHD- and OCD-related symptoms.

Crystalline dihydrochloride hydrate forms improve omecamtiv mecarbil solubility, stability, and low hygroscopicity for heart failure formulations.

Selective hydroxamates target Nav1.7 and Nav1.8 channels to relieve neuropathic pain while reducing adverse effects from non-selective blockers.

Aryl-piperidine derivatives inhibit tankyrase, suppress β-catenin, stabilize AXIN2, and improve anticancer activity with fewer side effects.

Selective aryl pyridine blockade of Nav1.7 and Nav1.8 targets pain pathways to relieve neuropathic pain with fewer adverse effects.

Acetone, methanol, salt separation, and filtration purify PS-enriched brain phospholipids without chloroform residues or silica gel chromatography.

An MPA suspension with docusate sodium and polyethylene glycol improves heat-stable shelf life and syringeability for long-acting subcutaneous contraception.

A prodrug of HMS5552 stays stable in gastric fluid, then hydrolyzes in the small intestine to improve absorption and diabetes treatment.

Novel heteroaromatic carboxamides improve plasma kallikrein inhibition while boosting selectivity, metabolic stability, and safety.

Changing the octahydrothienoquinoline drug salt from hydrochloride to succinate improves hygroscopicity, crystallinity, and storage stability.

An oral Monascinol composition reduces liver fat and AST/ALT while improving gut microbiota balance in obesity-related NAFLD.

Selective amide blockers target Nav1.7 and Nav1.8 to relieve neuropathic pain while reducing adverse effects from non-selective sodium channel inhibition.

Antibody-drug conjugates direct glucocorticoids to antigen-expressing cells, limiting non-target toxicity while maintaining treatment efficacy.

Multiple butylphthalide salt forms improve stability and bioavailability while supporting neuroprotection in ischemic and degenerative disorders.

Targeting CCL1 in Kupffer cells helps inhibit hepatic fibrosis while reducing the side effects of non-specific liver treatments.

A maleimide or cyclooctyne amino acid linker improves ADC blood stability, lowers polymer formation, and enables enzymatic toxin release.

Using galactose and fucose as monosaccharides promotes faster re-epithelialization, shortens healing time, and helps minimize scarring.

Specific CYP2E1 inhibitors target chronic inflammatory microenvironments to curb oxidative stress, tumor progression, and related IMDs.

ABP combinations target extracellular Ras without HLA restriction, while 3D tumor models improve detection and therapy testing on viable cells.

Lowering glycated chitosan below 420 kDa enables sterile filtration and purification while preserving dendritic cell CD40 activation.

Adult epicardial cells lose regenerative capacity after injury; targeted p21 inhibition with siRNA or CRISPR-Cas can reactivate regeneration.

Small-molecule OX2R agonists use tailored heterocycle structures to restore orexin signaling and promote wakefulness in narcolepsy models.

Learn how oral nebulization delivers nezulcitinib during high-flow nasal oxygen without reducing oxygen flow or using in-line delivery.

Heterocyclic structure changes create potent MEK/ERK inhibitors designed for CNS penetration and MAPK pathway suppression.

An iodine-containing copolymer makes porous embolic microspheres X-ray visible while preserving controlled degradation and delivery precision.

Cancer cells can resist cytotoxic therapy by upregulating BCL-XL; heterobifunctional compounds recruit VHL to trigger its ubiquitination and degradation.

Hydrophilic HPMC gel forms a tablet matrix that slows IMM-H014 diffusion, lowering peak concentration and extending therapeutic exposure.

Amorphous 6-OH CBDV is difficult to process; crystalline Forms A–E improve handling, stability, and pharmaceutical formulation.

Heat exposure can degrade e-vaping flavor; an ethanol-free gel with water and biopolymer helps maintain flavor integrity during vapor formation.

EDTA chelation and pH adjustment help stabilize liquid tizanidine, supporting accurate titration, dysphagia compliance, and equivalent bioavailability.

Specific LFA-1 I-domain mutations tune ICAM-1 binding so CAR-T cells kill overexpressing carcinoma cells while limiting healthy-tissue damage.

Combining ionizable, PEG-modified, and structural lipids helps encapsulate circular RNA, improve cytoplasmic delivery, and limit immune response.

Complementary dsRNA strands target ANGPTL8 to lower triglycerides while chemical modifications limit cytotoxicity and immune stimulation.

Combining CpG oligonucleotides with STING agonists strengthens Th1 and CD8+ T-cell responses while suppressing IgE production.

Single CDK or HDAC inhibitors can drive resistance; this case combines both functions in one heterocyclic compound for broader anti-tumor activity.

Topical oncokinase inhibitors with solubility enhancers and petrolatum target congenital hyperplasia and vascular discoloration.

A composite LNP carrier protects unstable nucleic acids, supports cellular uptake, and enables delivery beyond liver tissue.

Nasal delivery bypasses oral first-pass metabolism to provide rapid benzodiazepine absorption with easier self-administration.

Current NAFLD treatments may not suppress HSD17B13 effectively; hepatocyte-targeted RNAi lowers its mRNA and protein levels.

WS-12 ophthalmic formulations use PEG 400, hypromellose, pH buffering, and heat treatment to maintain stability without preservatives or refrigeration.

Halogen placement on isoindoline compounds supports oral protein regulation while enhancing GSPT1 degradation and anti-tumor activity.

See how AZD1656 cocrystals with fumaric, maleic, malonic, L-tartaric, or gentisic acid improve dissolution and stability.

Current orexin-related treatments are inadequate; modular sulfonamide structures target receptor activity for broader therapeutic use.

Conventional lipid drugs may reduce cholesterol but cause adverse effects; this high-EPA fish oil–TCM complex targets multiple blood lipid measures.

A 5H-pyrimido[5,4-b]indole scaffold improves immune stimulation while enabling antibody or PEG conjugation for targeted delivery.

LY2922470 improves renal function and inhibits renal fibrosis, offering a drug-based option for chronic kidney disease.

Existing cancer and autoimmune treatments may not inhibit two linked enzymes effectively; this chalcone targets ornithine decarboxylase and PAD4.

Low oral exposure limits rifabutin against multidrug-resistant A. baumannii; intravenous delivery raises Cmax and AUC for treatment.

Bicyclic heterocycle compounds target TEAD palmitoylation sites to disrupt YAP/TAZ binding and regulate Hippo signaling.

An aqueous R-ketamine formulation uses an amphiphilic excipient for rapid oral-mucosal absorption and high bioavailability.

These heterobifunctional compounds recruit CRBN to BCL-XL, driving ubiquitination and proteasomal degradation to sensitize cancer cells to apoptosis.

Autologous CD34+ cells are transduced with CD68-ET3-LV to sustain Factor VIII production and reduce repeated haemophilia infusions.

Enzymes KDO3 and KDO1 enable site-specific hydroxylation of cepafungin to create syrbactin analogs with stronger proteasome inhibition.

1,5-Naphthalenedisulfonic acid salts of ceragenins form crystalline products with improved stability and simpler synthesis.

Poorly stable STING agonists can limit systemic cancer activity; dual-function compounds pair STING activation with PI3K or IDO inhibition.

Localized anti-angiogenic delivery to ganglia induces neuronal apoptosis, targeting drug-resistant arrhythmia and chronic pain with lasting effects.

Crystalline forms, polymorphs, and salts of cudetaxestat address solubility and bioavailability limits while supporting stable, manufacturable autotaxin inhibition.

KCC2 modulation enhances chloride extrusion and neuronal inhibition, addressing inadequate control of refractory and benzodiazepine-resistant seizures.

pH-sensitive amino lipids keep carriers stable in circulation and trigger local release in acidic tumors or infected sites.

Specific MAPT antisense sequences and chemical modifications address the lack of disease-modifying therapy by reducing MAPT expression in tauopathies.

Enone prodrugs protect dopaminergic compounds from rapid metabolism, improving oral bioavailability and prolonging action in Parkinson's treatment.

Modified lipid structures improve nucleic acid encapsulation and delivery while addressing instability, low permeability, and immune activation.

Limited GEJ disease models make cancer research difficult; GEJ organoids support prolonged studies of PTAFR blockade and tumor growth.

Alternating supraphysiologic testosterone and androgen deprivation addresses AR-driven resistance in CRPC, with optional immune checkpoint blockade.

Controlled hydrolysis of alkylsulfenyl thiocarbonates tunes RSSH release while reducing electrophilic byproducts in oxidative-stress therapies.

Multiple coronavirus epitopes are combined in an RNA construct to stimulate CD8+ T cells and humoral immunity while reducing ADE risk.

Short protein-drug half-life drives frequent dosing; plasmid DNA constructs enable host cells to produce therapeutic proteins for months or years.

Growth hormone secretagogues paired with metformin or related drugs target insulin resistance, liver fat, and inflammation in NAFLD/NASH.

Existing HIV therapies can leave integrase untargeted; tetracyclic heterocyclic compounds block viral DNA integration.

Precise bupropion and dextromethorphan dose ranges are used to sustain Alzheimer's agitation improvement for at least four weeks.

TOMM6-interacting compounds bind mitochondrial outer membrane proteins to stabilize import machinery and prevent toxic protein aggregation.

Reversible hetero-bicyclic compounds inhibit Bruton's tyrosine kinase via non-covalent interactions, reducing off-target toxicity while maintaining efficacy.

Separation oil replaces air bubbles in the catheter lumen, preventing surface tension adhesion and improving implantation success rates.

A compound composition merges glucosamine with traditional Chinese medicine extracts to enhance bone and joint health.

Modular chemical structures inhibit alpha4beta7 integrin activity, resolving insufficient binding efficacy in autoimmune therapies.

A composite bone substitute material combines calcium sulfate and gentamicin sulfate to deliver sustained antimicrobial protection.

A composition combining leucine and vitamin B6 enhances energy metabolism through specific mass ratios.

Double-stranded nucleic acids mediate RNA interference to degrade CFB mRNA, resolving limited patient applicability of existing complement therapies.

Monthly sustained-release buprenorphine formulations deliver therapeutic plasma concentrations to maintain mu-opioid receptor occupancy.

Tailed mutant Trichomonas vaginalis purine nucleoside phosphorylase enzymes resolve low cleavage activity by selectively generating cytotoxic purine analogs.

NMN acts as an NAD+ precursor to activate sirtuin pathways, protecting photoreceptors from degeneration.

Segmenting heterocyclic structures into oxadiazole and oxazole series optimizes S1P1 receptor binding affinity while minimizing off-target effects on S1P3.

Amorphous doxepin in a mucoadhesive buccal film bypasses hepatic first-pass metabolism to increase bioavailability and reduce sleep onset latency.

Optimized aminoalkyl compound achieves transdermal analgesic delivery without penetration enhancers, resolving skin irritation and low permeation trade-offs.

Administering CXCR3 agonists before cancer therapy protects bone marrow, reducing myelosuppression and enabling higher treatment doses.

Substituted indole compounds inhibit Toll-like receptor 7, 8, and 9 signaling to resolve sustained aberrant activation in autoimmune disorders.

Formula I compounds target Class IIa HDACs to resolve specificity limitations in existing neurodegenerative treatments.

Formula X compounds modulate resistant EGFR and HER2 mutations, restoring therapeutic effectiveness against non-small cell lung cancer.

Isotopic substitution in quinolone inhibitors slows metabolic oxidation to extend half-life and reduce toxicity risks.

A cereblon-binding compound links to a KRAS G12C modulator to recruit proteasomal degradation of the target protein.

Lanthanide complexes enable selective cancer cell visualization and controlled drug release via receptor-mediated targeting.

Extended DsiRNAs achieve 99% KRAS inhibition at low concentrations, resolving potency and duration trade-offs.

Phosphorothioate ssONs induce IL-10 production to reduce inflammation without toxic side effects.

Administering antioxidant agents to treat chronic wounds by reducing oxidative stress and promoting tissue regeneration.

A composition of phenylalanine, serine, glutamine, and GABA enhances enkephalin activity to increase analgesia.

Low-concentration carbachol compositions resolve the contradiction between symptom reduction and prolonged duration by limiting miosis to 2-4 hours.

Lentinus edodes mycelium extract protects peripheral nerves from oxaliplatin-induced damage, allowing patients to continue effective cancer treatment.

A conductive hydrogel restores electrical impulse propagation across damaged myocardial tissue.

Novel 3-benzyl-azetidine derivatives selectively increase catecholamine levels in the frontal cortex.

Fused bicyclic 2,4-diaminopyrimidine derivatives inhibit ALK and c-Met kinases to treat proliferative disorders.

A bioactive lipophilic extract from Silybum marianum retains fatty acids via supercritical CO2 processing.

Weekly anti-CD37 immunoconjugate dosing reduces neutropenia while sustaining CD37 antigen exposure.

Enteric polymer coatings shield oral rapamycin nanoparticles from stomach acid, ensuring reliable bioavailability and biodistribution in intestinal absorption.

Simultaneous extrusion and curing create a contiguous silicone structure that eliminates junction barriers, preventing burst release patterns.

Segmented nicotine formulations maintain stable plasma concentrations to reduce dyskinesia while managing motor symptoms.

A fibrosis-causing agent combines polycations and polyanions to induce targeted tissue repair in lung structures.

N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide inhibits aberrant growth states.

Deleting the stg operon in attenuated Salmonella typhi enhances Peyer's patch targeting and IL-8 secretion to overcome low immunogenicity.

Asymmetric dihydrobenzo[b,f][1,4]thiazepine-8-carboxamides target D2 receptors to reduce off-target GPCR activity and adverse effects.

Retinoid and auranofin compounds treat drug-resistant bacterial and fungal infections while reducing toxic side effects.

Erythroid-specific promoter drives BCL11A shRNA to increase fetal hemoglobin production in modified hematopoietic cells.

Olaparib sustained release composition uses matrix polymers to control drug dissolution, reducing plasma concentration fluctuations and dose-limiting toxicity.

Administering a ubiquitin-activating enzyme inhibitor alongside radiation overcomes cancer cell resistance by impairing ubiquitin-dependent processes.

Selective crystallization isolates the E-isomer to maintain steric purity above 95%, resolving isomerization instability in pharmaceutical formulations.

Inhibiting the hypoxia-induced zinc transporter ZIP12 attenuates pulmonary vascular remodelling and provides a diagnostic marker for pulmonary hypertension.